Literature DB >> 1415201

Renal hemodynamics in recent-onset type II diabetes.

R Nowack1, E Raum, W Blum, E Ritz.   

Abstract

Glomerular hyperfiltration is thought to play an important role in the genesis of diabetic nephropathy. While hyperfiltration is well documented in early type I diabetes, the evidence for hyperfiltration in type II diabetes is conflicting. We investigated 16 nonproteinuric patients with recently diagnosed type II diabetes. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured as inulin clearance (CIN) and p-aminohippuric acid clearance (CPAH) using a constant infusion technique. Lean body mass was measured by densitometry (weighing under water). Renal hemodynamics were also measured in 31 healthy volunteers and six obese nondiabetic individuals. Median GFR in diabetics (133 mL/min/1.73 m2; range, 95 to 165) was significantly (P < 0.01) higher than in obese nondiabetic controls (median, 118; range, 95 to 139). Elevated GFR (ie, > 95th percentile of nonobese healthy controls) was found in 44% of patients. When GFR was factored for lean body mass, it was elevated in 50%. GFR did not correlate with fasting glucose, hemoglobin A1C (HbA1C), insulin-like growth factors, IGF-1 and IGF-2, or somatomedin-binding protein (SMBP). The findings document that hyperfiltration is common in recent-onset type II diabetics.

Entities:  

Mesh:

Year:  1992        PMID: 1415201     DOI: 10.1016/s0272-6386(12)70296-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

Review 1.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.

Authors:  Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles
Journal:  J Am Soc Nephrol       Date:  2017-01-31       Impact factor: 10.121

Review 2.  Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.

Authors:  Jay Garg; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

3.  A standard weight descriptor for dose adjustment in the obese patient.

Authors:  Stephen B Duffull; Michael J Dooley; Bruce Green; Susan G Poole; Carl M J Kirkpatrick
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate.

Authors:  E Premaratne; R J Macisaac; C Tsalamandris; S Panagiotopoulos; T Smith; G Jerums
Journal:  Diabetologia       Date:  2005-11-01       Impact factor: 10.122

Review 5.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

6.  Macroalbuminuria and renal pathology in First Nation youth with type 2 diabetes.

Authors:  Elizabeth A C Sellers; Tom D Blydt-Hansen; Heather J Dean; Ian W Gibson; Patricia E Birk; Malcolm Ogborn
Journal:  Diabetes Care       Date:  2009-02-19       Impact factor: 17.152

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.